This document provides a summary of the 2015 edition of the Nuclear Medicine World Market Report & Directory published by MEDraysintell. It analyzes 335 radiopharmaceuticals and radionuclides and 160 companies in the nuclear medicine market. The global nuclear medicine market is expected to reach $24 billion by 2030, growing at an annual rate of 11%. Growth will be driven by new radiotherapeutic products reaching the market and an annual growth rate of 26% for radiotherapeutics from 2014-2030. The report also profiles over 60 companies researching radiopharmaceuticals and radiotherapeutics and discusses recent consolidation in the market through mergers and acquisitions.

1. MEDraysintell
NUCLEAR
MEDICINE
WORLD MARKET REPORT & DIRECTORY
RADIONUCLIDES, RADIOPHARMACEUTICALS,
MARKET PIPELINE AND R&D PORTFOLIO,
MARKET DATA, PRODUCT PRICING, COMPANIES PROFILES
EDITION 2015
© 2015
www.medraysintell.comA report written by Paul-Emmanuel Goethals & Richard Zimmermann

2. Medical Radiation Strategic Intelligence Experts
Bringing value to Businesses and Investors! © MEDraysintell 2015
MEDraysintell
Disclaimer
This MEDraysintell presentation and information contained herein, coming from the report “Nuclear Medicine World
Market Report & Directory, Edition 2015” is believed to be accurate at the time of publication; it has been gathered in
good faith from several sources, but the authors are not in a position to guarantee its accuracy. The authors do not
accept any responsibility for the content of this report. Information contained herein may be of a speculative nature
and must be used with careful consideration. The authors assume no liability for any loss or damage – including but
not limited to lost time, lost money, lost profits, lost customers – that may result from any use of the information or
actions taken based on any analyses, projections, discussions, recommendations, or conclusions of any kind
presented in this report.

3. Medical Radiation Strategic Intelligence Experts
Bringing value to Businesses and Investors! © MEDraysintell 2015
MEDraysintell
Nuclear Medicine,Edition 2015
THE MOST COMPREHENSIVE EVALUATION REPORT AND DIRECTORY
OF NUCLEAR MEDICINE, WRITTEN BY EXPERTS,
PROVIDING DETAILED INFORMATION ON PRODUCTS AND COMPANIES
ACTIVE IN THIS MARKET
This 920-page report is providing a description and analysis of 335
radiopharmaceuticals and radionuclides and 160 companies and institutions
 New opportunities lie ahead in nuclear medicine, especially
in the radiotherapeutic area
 New radiotherapeutics to reach market before end of 2020
 Opportunities exist for larger groups or investors to finance such
development, to merge with key partners and/or to acquire
companies.

4. Medical Radiation Strategic Intelligence Experts
Bringing value to Businesses and Investors! © MEDraysintell 2015
MEDraysintell
Nuclear Medicine,Edition 2015
 The global market is expected to reach US$ 24 billion by
2030, showing an annual average growth of 11%
 The diagnostic radiopharmaceutical market is expected to grow, on
average, by 6% a year, mainly driven by volume with limited impact
from new tracers
 The therapeutic radiopharmaceutical market is expected to grow
26% annually from 2014 to 2030

5. Medical Radiation Strategic Intelligence Experts
Bringing value to Businesses and Investors! © MEDraysintell 2015
MEDraysintell
Nuclear Medicine,Edition 2015
 Nearly 70 companies are active in the global nuclear
medicine market, selling radiopharmaceuticals and
radiotherapeutics, with three dominant players
© MEDraysintell 2015

6. Medical Radiation Strategic Intelligence Experts
Bringing value to Businesses and Investors! © MEDraysintell 2015
MEDraysintell
Nuclear Medicine,Edition 2015
 Over 60 companies are currently researching and
developing one or more radiopharmaceuticals /
radiotherapeutics from their own pipeline
 Out of these companies doing R&D, over 35 have not yet marketed
a radiopharmaceutical product
Radiotherapeutics
under development

7. Medical Radiation Strategic Intelligence Experts
Bringing value to Businesses and Investors! © MEDraysintell 2015
MEDraysintell
Nuclear Medicine,Edition 2015
 Conventional pharmaceutical industry has gradually
become interested in nuclear medicine with some recent
M&A activities
 Bayer acquired Algeta
 Sun Pharmaceutical Industries acquired Pharmalucence
 Otsuka Pharmaceuticals entered into a global licensing and
collaboration agreement with NuView Life Sciences
 Norgine entered into a partnership with Navidea
 Ipsen acquired OctreoPharm Sciences
 The market saw some major recent consolidations
 AAA acquiring Atreus
 IHS acquiring IBA Molecular North America to merge with Zevacor

8. Medical Radiation Strategic Intelligence Experts
Bringing value to Businesses and Investors! © MEDraysintell 2015
MEDraysintell
Contact
Paul-Emmanuel Goethals, MBA
Louvain-la-Neuve, Belgium
peg@medraysintell.com
Phone: +32 491 080 968
Dr. Richard Zimmermann, PhD
Lalaye, France
rz@medraysintell.com
Phone: +33 6 82 80 06 00
MEDraysintell was created in 2013 by Paul-Emmanuel Goethals (CSIntell)
and Richard Zimmermann (Chrysalium Consulting). It combines over 40
years of experience in radiotherapy, particle therapy and nuclear medicine.
We aim to form an international team of experts in the field of Medical
Radiation industry to provide Strategic Intelligence in nuclear medicine,
radiotherapy, proton therapy and brachytherapy to help our clients better
understand the markets, competitive environment as well as the potential of
merger and acquisitions (M&A) and technology development.
MEDraysintell wants to support in their decisional process manufacturers of
radiopharmaceuticals or therapeutic radioisotopes, suppliers of equipment
and software as well as investors interested by this industry.
www.medraysintell.com
Copyright © 2015, MEDraysintell (CSIntell and Chrysalium Consulting), All rights reserved.
To request a detailed table of contents of this report and to order, please send
an e-mail with your contact details to: peg@medraysintell.com
Price: EUR 7,000